Stay updated on Pembrolizumab for EGFR+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for EGFR+ NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab for EGFR+ NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe study record page now displays a 403 Forbidden error, replacing the previous content and removing several study documents and related links from the page.SummaryDifference19%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedRevision updated from v3.6.5 to v3.6.6 on the page, indicating a minor backend/template update. No study content or data appears to be changed.SummaryDifference0.1%

- Check52 days agoChange DetectedA software revision label on the page was updated from v3.6.4 to v3.6.5. This reflects a version bump and does not modify the study information or functionality visible to users.SummaryDifference0.1%

- Check66 days agoChange DetectedA new revision tag `Revision: v3.6.4` was added, replacing the previous `Revision: v3.6.3`. This indicates an update to the page's build or versioning metadata without modifying the study details presented.SummaryDifference0.1%

- Check88 days agoChange DetectedThe page shows Revision: v3.6.3, replacing the previous Revision: v3.6.2, indicating a new version of the page template or system.SummaryDifference0.1%

- Check96 days agoChange DetectedA newer revision tag (v3.6.2) replaces the previous v3.6.0, indicating an updated version of the page documentation.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for EGFR+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for EGFR+ NSCLC Clinical Trial page.